EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors

Launched by GUANGXI MEDICAL UNIVERSITY · Sep 21, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a procedure called EUS-FNI, which stands for Endoscopic Ultrasound-Fine Needle Injection, to treat pancreatic neuroendocrine tumors (pNETs) in patients with a rare genetic condition known as Multiple Endocrine Neoplasia Type 1 (MEN1). The goal is to see how safe and effective this procedure is for patients who cannot or choose not to have surgery for their tumors.

To be eligible for this trial, participants should have been diagnosed with MEN1-related pNETs through specific tests and should not be planning to have surgery. Additionally, they need to be able to provide informed consent, meaning they understand the trial and agree to participate. However, individuals who have certain health issues that make them unsuitable for the procedure, such as blood clotting problems or severe heart and lung conditions, will not be included. If you join the trial, you can expect careful monitoring and support throughout the process as researchers look to determine how well this treatment works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with MEN1-1-related pNETs are evaluated by histopathology and genetic testing.
• • 2. Patients who refuse surgery.
• • 3. Patients who have given their fully informed consent.
• Exclusion Criteria:
• • 1. Patients who are not suitable for the endoscopic procedure.
• • 2. Patients who have blood coagulation dysfunction, mental disorders, mild or severe cardiorespiratory.